Scalper1 News
Top-rated specialty drug maker Horizon Pharma (HZNP) beat Q1 sales estimates and settled a patent suit Friday, but its stock seesawed. Horizon’s earnings excluding one-time items rose 62% over the year-earlier quarter to 21 cents a share, in line with analyst consensus, according to Thomson Reuters. Sales jumped 118% to $113.1 million, about $9 million above the Street’s average estimate. Horizon also boosted its guidance to reflect the Scalper1 News
Scalper1 News